We have developed and patented an exosome-based targeted drug delivery vehicle for metastatic breast cancer.
We are developing a guided exosome-based drug-delivery vehicle, ExoDS, to specifically target and eliminate cancer cells and cancer stem cells, which are responsible for tumor relapse and metastasis. Our delivery system can reduce chemotoxicity by 70% and increase the efficiency of the chemotherapy drug by 22%.
Big BIRAC grant, HDFC Parivartan, and seed investment from Unicorn India Ventures
One patent granted, one patent filed.
OIST Innovation Acceleration Program, Okinawa, Japan; X-Tech Innovator Award, Japan
Co-Founders Abhishek Dutta and Swastika Paul bring 20 years of combined research experience in Biotech, evidenced by 27+ publications.
CEO
CSO
